Scarica l'app Stockscreener
1.15
8.73%
-0.11
Dopo l'orario di chiusura:
1.15
Precedente Chiudi:
$1.26
Aprire:
$1.25
Volume 24 ore:
204.42K
Relative Volume:
0.56
Capitalizzazione di mercato:
$27.62M
Reddito:
-
Utile/perdita netta:
$-21.54M
Rapporto P/E:
-1.1611
EPS:
-0.9904
Flusso di cassa netto:
$-19.60M
1 W Prestazione:
-16.06%
1M Prestazione:
+12.75%
6M Prestazione:
-59.51%
1 anno Prestazione:
-83.28%
Intervallo 1D:
$1.13
$1.28
Intervallo di 1 settimana:
$1.13
$1.73
Portata 52W:
$0.90
$8.49
Actuate Therapeutics Inc Stock (ACTU) Company Profile
Nome
Actuate Therapeutics Inc
Settore
Industria
Telefono
847-986-4190
Indirizzo
1751 RIVER RUN, FORT WORTH
Compare ACTU vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ACTU
Actuate Therapeutics Inc
|
1.15 | 30.26M | 0 | -21.54M | -19.60M | -0.9904 |
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
Actuate Therapeutics Inc Stock (ACTU) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-26 | Iniziato | B. Riley Securities | Buy |
| 2025-04-22 | Iniziato | Craig Hallum | Buy |
| 2025-03-17 | Iniziato | H.C. Wainwright | Buy |
Actuate Therapeutics Inc Borsa (ACTU) Ultime notizie
Actuate to Present at the H.C. Wainwright 28th Annual Global Investment Conference - GlobeNewswire
Actuate Therapeutics Reports Synergistic Preclinical Activity of Elraglusib with RAS-Targeted Agents in Pancreatic Cancer Models - quiverquant.com
All You Need to Know About Actuate Therapeutics, Inc. (ACTU) Rating Upgrade to Buy - Yahoo Finance
12 Health Care Stocks Moving In Thursday's Intraday Session - Sahm
Actuate (ACTU) Results Check: EPS Does Not Reach the Reported Estimate under the Current Snapshot; Closing Reaction: The Stock Gains 16.04% for the Current SessionInvestor Earnings Call - vinanet.vn
Actuate (ACTU) Results Review: The EPS Result Is Below Expectation in the Available Record; Share Move: Shares Move 0.95% Up at the CloseRevenue Estimate Trend - vinanet.vn
Actuate Therapeutics (ACTU) Holds $1.00 After 1.31% Gain, Pinned Between Key Support and ResistanceBullish Percent Index - vinanet.vn
Actuate Therapeutics stock gets FDA clearance for elraglusib trial By Investing.com - Investing.com Canada
Actuate Therapeutics (ACTU) Gains 3.58% to $1.01, Approaches Key Resistance at $1.06Bullish Pattern Stocks - vinanet.vn
Actuate Therapeutics Inc (ACTU) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Actuate Therapeutics (ACTU) Pushes 3.58% Higher, Tests $1.06 Resistance ZoneButterfly Setup - dars.gov.et
Actuate Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Actuate Therapeutics (ACTU) CEO RSUs Vest, 120,521 Shares Withheld for Taxes - Stock Titan
Actuate Therapeutics (NASDAQ: ACTU) narrows loss but warns on cash runway - Stock Titan
Actuate Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Actuate Therapeutics (ACTU) Holds Near $0.97 as Support Test LoomsButterfly Setup - vinanet.vn
ACTU Q1 2026 Earnings: Wider-than-Expected Loss Reflects Ongoing R&D InvestmentEarnings Outlook Update - Vinanet
ETFs Investing in Actuate Therapeutics, Inc. Stocks - TradingView
Actuate Therapeutics Inc (ACTU) Stock News Today - TradingKey
Actuate Therapeutics (ACTU) Surges 8.85% to $1.23 as Buyers Defend Key SupportOvernight Profile - vinanet.vn
CNSY Stock Price and Chart — NASDAQ:CNSY - TradingView
Actuate Therapeutics, Inc. Revenue Breakdown – NASDAQ:ACTU - TradingView
Rodman & Renshaw Initiates Actuate Therapeutics(ACTU.US) With Buy Rating, Announces Target Price $6 - Moomoo
Actuate Therapeutics stock initiated with buy rating at Rodman & Renshaw - Investing.com
Actuate Therapeutics Inc (ACTU) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Actuate Therapeutics Inc (ACTU) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Actuate Therapeutics Inc (ACTU) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Actuate Therapeutics Inc (ACTU) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Actuate Therapeutics Inc (ACTU) Valuation: PE, PB & Fair Value Analysis - TradingKey
ACTU|Actuate Therapeutics Inc|Price:1.170|Chg%:-0.010 - TradingKey
Actuate Therapeutics Inc (ACTU) Cash Flow - TradingKey
ACTU|Actuate Therapeutics Inc|Price:1.230|Chg%:+0.170 - TradingKey
Actuate Therapeutics Inc (ACTU) Balance Sheet - TradingKey
Actuate Therapeutics Inc (ACTU) Income Statement - TradingKey
Actuate Therapeutics Inc (ACTU) Institutional Confidence - TradingKey
Actuate Therapeutics Inc (ACTU) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
ACTU|Actuate Therapeutics Inc|Price:1.140|Chg%:-0.040 - TradingKey
ACTU|Actuate Therapeutics Inc|Price:1.185|Chg%:-0.075 - TradingKey
Actuate Therapeutics Inc (ACTU) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Actuate Therapeutics Q1 2026 Earnings: EPS Miss and Pre-Revenue Status Weigh on StockOne-Time Gain Impact - vinanet.vn
Actuate Therapeutics Inc. (ACTU) Q1 2026 Earnings: EPS Miss of 8.6% Reflects Continued Pre-Revenue Investment PhaseShare Dilution Risk - dars.gov.et
Actuate Therapeutics, Inc. Files Form 8-K: NASDAQ Compliance Update and Company Details (July 2026) - Minichart
Actuate Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
ACTU Q1 2026 Earnings: EPS Misses Estimates as Stock Declines 13%EPS Consistency Score - vinanet.vn
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Actuate Therapeutics (ACTU) Surges 17.8% as Momentum Builds After Support TestLow Risk Entry Stocks - vinanet.vn
ACTU Q1 2026 Earnings: EPS Misses Estimates as Pipeline Progress Drives Stock RallyDividend Growth Analysis - dars.gov.et
Actuate Therapeutics, Inc.(NasdaqGM: ACTU) dropped from Russell 2000 Dynamic Index - marketscreener.com
Actuate Therapeutics, Inc.(NasdaqGM: ACTU) dropped from Russell 3000E Index - marketscreener.com
Actuate Therapeutics, Inc.(NasdaqGM: ACTU) dropped from Russell 2500 Index - marketscreener.com
Actuate Therapeutics Inc Azioni (ACTU) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):